S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.65 (-0.04%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

$26.75
-0.50 (-1.83%)
(As of 11:03 AM ET)
Today's Range
$26.63
$27.30
50-Day Range
$26.16
$30.74
52-Week Range
$14.89
$32.53
Volume
54,735 shs
Average Volume
722,952 shs
Market Capitalization
$2.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.00

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
98.2% Upside
$54.00 Price Target
Short Interest
Bearish
11.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.53mentions of Rocket Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$9.22 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.94) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

185th out of 939 stocks

Pharmaceutical Preparations Industry

74th out of 434 stocks

RCKT stock logo

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

RCKT Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
RCKT Apr 2024 17.500 put
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RCKT
Employees
268
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$54.00
High Stock Price Target
$65.00
Low Stock Price Target
$47.00
Potential Upside/Downside
+98.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-245,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.46 per share

Miscellaneous

Free Float
62,357,000
Market Cap
$2.47 billion
Optionable
Optionable
Beta
1.08

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 49)
    CEO & Director
    Comp: $1.05M
  • Ms. Kinnari Patel M.B.A. (Age 45)
    Pharm.D., President & COO
    Comp: $849.93k
  • Mr. John C. Militello CPAMr. John C. Militello CPA (Age 51)
    VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $501.42k
  • Mr. Mayo Pujols (Age 55)
    Chief Technical Officer & Executive VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 50)
    Senior VP & Chief Business Officer
    Comp: $619.13k
  • Mr. Martin Louis Wilson J.D. (Age 48)
    General Counsel, Chief Compliance Officer & Senior VP
    Comp: $149.95k
  • Kevin Giordano
    Director of Corporate Communications
  • Ms. Isabel Carmona J.D.
    Senior VP & Chief Human Resources Officer
  • Mr. Jonathan Schwartz M.D. (Age 59)
    Chief Gene Therapy Officer & Senior VP of Clinical Development
    Comp: $557.79k
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Development Officer of LVV & Senior VP

RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price target for 2024?

8 brokers have issued 1 year price objectives for Rocket Pharmaceuticals' shares. Their RCKT share price targets range from $47.00 to $65.00. On average, they predict the company's share price to reach $54.00 in the next twelve months. This suggests a possible upside of 98.2% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2024?

Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of the year. Since then, RCKT shares have decreased by 9.1% and is now trading at $27.25.
View the best growth stocks for 2024 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings results on Monday, February, 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.14. During the same period in the prior year, the firm posted ($0.92) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.06%), Vanguard Group Inc. (6.04%), Vanguard Group Inc. (6.02%), Westfield Capital Management Co. LP (4.37%), Price T Rowe Associates Inc. MD (2.92%) and Price T Rowe Associates Inc. MD (2.92%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Martin Wilson and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners